Articles tagged with T Cell Responses
A research team led by Professor Wolfgang Kastenmüller has discovered that unconventional T cells play a crucial role in triggering site-specific immunity in distinct lymph nodes. The study reveals that different subtypes of unconventional T cells migrate to specific lymph nodes, influencing the immune responses there.
Boosting with either Janssen or Pfizer-BioNTech vaccine boosts humoral and cellular immune responses. Boosting with Janssen vaccine provides durable antibody and T-cell responses for at least four months.
A novel T cell bispecific antibody targeting EGFRvIII mutant glioblastoma has demonstrated potent anti-tumor activity in preclinical models. The therapy harnesses the power of the immune system to selectively target and destroy cancer cells, offering a safer treatment option for patients.
The new phage T4-COVID-19 vaccine elicits superior mucosal immunity in mice, inducing robust humoral and cell-mediated immune responses. The vaccine provides complete protection against SARS-CoV-2 variants with minimal lung lesions and no impact on gut microbiota.
Researchers used a new 3D imaging technique to analyze the interaction between T-cell therapies and solid mini-tumors, revealing a wide variety of behaviors in engineered T cells. The study identified specific gene signatures of highly potent T cells that can target multiple tumor cells.
Researchers discovered cancer cells produce a unique collagen that alters the tumor microbiome and promotes cancer progression. Loss of this collagen reduces cancer cell proliferation and boosts anti-tumor immune response, offering a potential therapeutic strategy.
Researchers found that highly specialized T cells, designed to eliminate infected cells, remained active in the blood of all previously SARS-CoV-2-infected patients for at least 20 months. These T cells did not disappear or wane even at long follow-up, suggesting a vital aspect of protective immunity that persists years after COVID-19.
Researchers developed a new blood test that can indicate cellular immunity to SARS-CoV-2 within 48 hours. The test distinguishes between post-infection and post-vaccination immunity, enabling quick diagnosis for patients unable to produce antibodies. Long-lasting T-cell responses may protect against severe disease in re-infections.
Studies in rats have found that T-cells produce reactive oxygen species (ROS) that contribute to preeclampsia complications. Researchers are exploring ways to dampen this response to reduce the risk of premature birth or worse outcomes for mother and child.
Researchers at the University of South Australia have discovered that combining anti-rejection medication with immune checkpoint inhibitors can significantly reduce the risk of organ rejection and eliminate cancer cells in a quarter of patients. The study involved 22 patients with renal transplants and incurable locally advanced or met...
A new atlas of tissue-resident memory T cells reveals their adaptation to distinct tissue environments, offering insights into immune defense strategies. The study's findings could inform the development of targeted vaccines and therapies, leveraging 'first responders' in tissues vulnerable to infection.
Researchers at the University of Birmingham have identified a 'cellular brake' protein that may help prevent autoimmune responses in lung cancer patients undergoing immunotherapy treatment. This finding could enable clinicians to closely monitor high-risk patients and develop preventative strategies.
Researchers developed a rapid blood assay that measures the magnitude and duration of immunity to SARS-CoV-2, allowing large-scale monitoring of population immunity. The test takes less than 24 hours to perform and is scalable to use broadly in the population.
A new PET imaging agent, 18F-AlF-FAPI-74, has been found to effectively monitor and predict treatment response of an up-and-coming cancer therapy. This non-invasive imaging approach can help inform clinical decision-making early in the course of treatment.
A commercial T cell test found that age and time since infection are significant factors related to the magnitude of immune responses to COVID-19. In vaccinated individuals, only increasing age was associated with poor T cell responses, while time from vaccination or type of vaccine had no effect.
A new study found that patients with long COVID have virus-specific T cell levels over 100 times higher than those who recovered from the disease. The research team's findings suggest hidden viral reservoirs may be causing long-term symptoms, guiding future treatments towards vaccines and antiviral medications.
A new study published in Cell compares the four types of COVID-19 vaccines and reveals that most people retain some immune response to SARS-CoV-2. The researchers found that immune memory may not prevent infection but helps fight severe disease.
A recent study at Cedars-Sinai Medical Center found that biologic drugs for inflammatory bowel disease may improve the T-cell immune response in patients vaccinated against COVID-19. This could potentially offer protection against severe disease. The study suggests that these treatments may be used to monitor vaccine and booster outcomes.
Researchers at the University of Chicago Medicine Comprehensive Cancer Center and the University of Amsterdam have identified a new mechanism that prompts T cell responses, including MHC-I cross-dressing. This discovery may lead to improved vaccine design and targeted cancer treatment strategies.
Researchers have found that gamma delta T cells can be trained to become extreme killers by recognizing abnormal target cells. This discovery has implications for developing novel cellular therapies to treat cancer and infectious diseases.
A groundbreaking study has discovered that the cornea produces a delicate immune response to fight viral infections without damaging vision. Long-living memory T cells have been found patrolling and fighting viral infections in the cornea, upending previous thought on T cell presence in healthy corneas.
Studies found people infected and vaccinated had similarly robust antibody responses against variants alpha through omicron; Immune memory cells against common cold coronaviruses may be markers of longer immunity. Researchers hope to improve vaccines with these insights.
Researchers discovered that adaptive immune response against TB matures over time, with key players in immunity becoming activated by three months after infection. The emergence of these activated T cells is inversely correlated with the number of granuloma-contained live bacteria, suggesting they play critical roles in bacterial control.
Researchers found that a single mRNA vaccine booster shot can provide the same level of protection as three doses, making it a promising investment for resource-poor countries. The study suggests that this strategy could benefit billions of people worldwide and help combat emerging COVID-19 variants.
A new study by Weill Cornell Medicine investigators found that T cells' genetic program and developmental path affect their response to immunotherapy. The results suggest that infiltrating T cells don't all meet the same fate in every tumor, with long-lived memory programs correlating strongly with overall survival
A study found that vaccines induce immune responses beyond neutralizing antibodies, involving T cells and the Fc receptor, to control viral replication and prevent severe disease. The researchers observed dose-dependent effects on these immune mechanisms, providing insights for future vaccine design and boosting.
Researchers at the Babraham Institute found that two RNA binding proteins, ZFP36 and ZFP36L1, play a crucial role in T cell development and function. The absence of these proteins enhances the potency of T cells during viral infections, leading to improved cytotoxic immune responses.
Researchers found that vitamin E boosts immunotherapy responses by stimulating dendritic cell activity, leading to improved antigen presentation and enhanced antitumor immunity. Vitamin E treatment also showed promise in combining with cancer vaccines and immunogenic chemotherapies.
WEHI researchers have found a way to release the 'handbrake' hold on Treg cells, enabling them to clear disease and infections faster. This breakthrough could lead to better treatment options for cancers and infections, where rapid clearance of unhealthy cells is crucial.
Researchers have made a breakthrough in enhancing the antiviral T cell response triggered by therapeutic vaccines for chronic hepatitis B. By removing natural killer cells and activating them with cytokines, they boosted the control of HBV infection.
Researchers at La Jolla Institute for Immunology discovered a Zika virus mutation that boosts its ability to replicate and infect humans. This mutation allows the virus to evade protective immunity from previous dengue exposure, increasing its transmission potential.
A new peptide-based vaccine, CoVac-1, has been shown to induce a T cell-dependent response in 93% of patients with B-cell deficiencies, including those with leukemia and lymphoma. The vaccine's T cell immunity exceeds that of individuals without immune deficiency or those who have received standard COVID-19 vaccines.
Researchers discovered that obesity changes molecular underpinnings of allergic inflammation in both mice and humans. The treatment in obese mice makes their skin worse instead of healing, but a specific drug can 'de-fatten' obese mice without changing body weight.
Researchers found that people who had COVID-19 and then got vaccinated generated an immune response more specific to fighting viral infections, producing a broader antibody response. This hybrid immunity also produced a cellular immune response called Th1 response, which is antiviral.
Researchers found that vaccine-induced T cells remain stable for up to 15 months after vaccination or infection, recognizing the SARS-CoV-2 spike protein. This long-lasting immune response is crucial in supporting the development of antibodies against the virus.
Research team finds mutations leading to omicron variant don't affect immune response in people with pre-existing immunity. This suggests individuals who were previously infected or vaccinated may still be protected against breakthrough infections, but humoral immunity may fail.
The investigational vaccine targets both the spike and nucleocapsid proteins, producing neutralizing antibodies and inducing T cell responses against SARS-CoV-2. COH04S1 is being studied in Phase 2 trials for immunocompromised patients and as a booster for healthy adult volunteers.
A collaborative study from Monash University has identified a new immune checkpoint, PTP1B, that can be exploited for cancer therapy. Inhibiting this protein in T cells enhances the body's immune response to cancer, helping to repress tumour growth.
Researchers have revealed that during Type 1 Diabetes development, pancreatic duct cells reprogram to suppress autoimmune T cell responses. This discovery advances understanding of the disease by creating a map of pancreatic islet cells over time.
Researchers discovered a viral infection can trigger autoimmunity in mice by disrupting the thymus's screening process for self-destructive T cells. Infection with murine roseolovirus led to autoimmune gastritis months later, highlighting a previously unknown way viruses can trigger autoimmunity.
Scientists at Hackensack Meridian Center for Discovery and Innovation have discovered a novel mechanism of immune 'memory' that could improve vaccine effectiveness. The Tcf1 transcription factor plays a crucial role in recognizing threats the immune system has faced before, and researchers believe it may be possible to enhance this imm...
A new study from the La Jolla Institute for Immunology reveals that two groups of regulatory CD4+ T cells develop at different times to combat acute inflammation. The early Tregs reduce autoimmune damage, while the second wave shuts down the entire immune response to signal infection clearance.
New study reveals that T-cell responses against the SARS-CoV-2 spike protein can predict protection against infection. In healthy individuals, T cells with a specific cytokine profile offered immunity against COVID-19. In contrast, cancer patients showed lower T-cell responses and increased susceptibility to infection.
Researchers at Johns Hopkins Medicine discovered a peptide on the SARS-CoV-2 spike protein that triggers an immune response in humans and is also recognized by cells of the immune system, suggesting potential for protection against future zoonotic outbreaks. The study supports the development of multivalent vaccines against a broad spe...
A recent study published in Cell found that T cell responses are still robust against the Omicron variant in most individuals with prior SARS-CoV-2 infection or vaccination, offering protection against severe disease. Booster vaccines can enhance T cell responses, substantially increasing immunity against severe COVID-19.
Researchers at Gladstone Institutes and UC San Francisco have developed a CRISPR activation method that allows them to activate genes in human immune cells, revealing key regulators of cytokine production. This breakthrough accelerates immunotherapy research and may lead to more powerful cancer treatments.
Immunosequencing of T cells combined with machine learning techniques reveals that participants with higher numbers of pre-existing memory CD4 T cells develop immunity more quickly and produce more antibodies following vaccination. This study has significant implications for immunity and vaccine development efforts.
Four COVID-19 vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2. These T cells can recognize variants of concern, including Delta and Omicron. Fully vaccinated people have fewer memory B cells and neutralizing antibodies against the Omicron variant.
Researchers at Karolinska Institutet found that memory T cells formed after previous infection or mRNA vaccination can still recognize the omicron variant, suggesting protection against severe disease. The study also suggests booster immunization may provide benefits beyond neutralizing antibodies.
Researchers found that T cells induced by previous common cold coronavirus infections can recognize and target internal proteins of SARS-CoV-2, providing a potential new vaccine target. This immunity offers long-lasting protection as T cell responses persist longer than antibody responses.
Researchers have discovered that individuals with a specific HLA type can mount a strong killer T cell response to COVID-19 due to cross-reactivity with seasonal coronaviruses. This finding may lead to the development of new vaccines targeting this immune response.
The SARS-CoV-2 Alpha variant adapted to avoid triggering the innate immune response by increasing expression of antagonism proteins, which disable the body's first line of defense. This allows the virus to replicate under the radar in early stages of infection, significantly increasing its chances of infecting a person.
A novel vaccine, TOH-Vac1, replicates inside the body's cells and generates a powerful immune response in mice and monkeys. The vaccine is based on a strain of vaccinia virus used to vaccinate against smallpox and can be programmed to protect against multiple variants.
Research from Queen Mary University of London and Cardiff University found that certain MS treatments can reduce Covid-19 vaccine effectiveness in people with MS. The largest peer-reviewed study on the topic provides high-quality evidence to inform clinicians' guidance on treatment options.
Researchers at La Jolla Institute for Immunology identified Th1* cells as a key marker in the body's immune signature following BCG vaccination. The study found that these cells respond well to the vaccine and can help fight the Mycobacterium tuberculosis bacterium that causes TB.
Researchers at UCLA have identified rare T cells capable of targeting a protein found in SARS-CoV-2 and other coronaviruses. By adding a fragment of this protein to vaccines, they hope to create a longer-lasting immune response and increase protection against new variants. This breakthrough could lead to more effective COVID-19 vaccines.
Researchers discovered that infections improve the production and function of naïve T cells, the body's first line of defense against disease. This mechanism involves interleukin 7 and MHC molecules, which signal naïve T cells to stay alive and receive optimal metabolic signals.
A new study reveals that gamma delta T cells play a critical role in promoting clinical protection against malaria. The unique T cell receptor on these cells enables them to recognize and tolerate Plasmodium falciparum parasite fragments, providing a vital component of an effective immune response.
A new approach for identifying shared patterns in immune cell receptor sequences may help determine if a person has previously been infected or vaccinated against a given pathogen. Researchers have developed software called tcrdist3 to facilitate this process.
Researchers at Monash University have discovered how gamma delta T cells recognize the MHC-like molecule MR1, providing key insights into the immune system's ability to detect infections and diseases. The study sheds light on the unique ways these cells interact with MR1, paving the way for new immunotherapies.